Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination With Tremelimumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT02558894 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02558894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02558894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination With Tremelimumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
November 16, 2015
Completion date
June 15, 2017
Enrollment
65 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic ductal adenocarcinoma